Please assess the completion status of the following clinical trial:

Trial Title: Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65 years~* Depressed male and female patients according to DSM-V \& minimum of 17-items Hamilton Depression Score of 18~* healthy controls~* informed consent signed~Exclusion Criteria:~* Current use of antidepressants, antipsychotics, or mood stabilizer~* Relevant medical or neurological disorders~* Pregnancy or unsure contraception~* Relevant psychiatric comorbidity (bipolar or psychotic disorders)~* Active alcohol or other substance abuse/dependance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Placebo+Placebo (Type: PLACEBO_COMPARATOR): Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.
- Fludrocortisone+Placebo (Type: ACTIVE_COMPARATOR): Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH~Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.
- Placebo+D-Cycloserine (Type: ACTIVE_COMPARATOR): Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.~D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd
- Fludrocortison+D-Cycloserine (Type: ACTIVE_COMPARATOR): Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH~D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd

Based on this trial design, predict the completion outcome and termination type (if applicable).